Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R2OU
|
|||
| Former ID |
DNCL001939
|
|||
| Drug Name |
Irdabisant
|
|||
| Synonyms |
CEP-26401
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Phase 1 | [1] | |
| Company |
Cephalon
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H23N3O2
|
|||
| Canonical SMILES |
CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3
|
|||
| InChI |
1S/C18H23N3O2/c1-14-4-2-11-21(14)12-3-13-23-16-7-5-15(6-8-16)17-9-10-18(22)20-19-17/h5-10,14H,2-4,11-13H2,1H3,(H,20,22)/t14-/m1/s1
|
|||
| InChIKey |
XUKROCVZGZNGSI-CQSZACIVSA-N
|
|||
| CAS Number |
CAS 1005402-19-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01903824) Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects. U.S. National Institutes of Health. | |||
| REF 2 | CEP-26401 (irdabisant), a potent and selective histamine H receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther. 2012 Jan;340(1):124-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.